Necrosulfonamide

Necrosulfonamide 是一种 MLKL 和 Gasdermin D (GSDMD) 抑制剂,可分别抑制细胞坏死性凋亡 (necroptosis) 和焦亡 (pyroptosis),其不影响上游信号激活,而是特异性抑制下游执行器的寡聚化步骤,同时可降低参与坏死性凋亡和焦亡的关键激酶 NLRP3 和 caspase-1 的表达,激活 Nrf2 通路及下游抗氧化酶,并下调多种炎症因子,从而通过调节这两条重要的程序性坏死通路,在神经退行性疾病 (如帕金森病)、组织损伤和缺血-再灌注损伤、炎症性肠病、骨关节炎和骨折修复以及脱发等多种疾病中发挥重要作用。
产品编号: MS-W65149 纯度: 98.61% CAS No.: 1360614-48-7 分子式: C18H15N5O6S2 分子量: 461.47
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
10mM * 1mL in DMSO
询价
3-5 天
5mg
询价
3-5 天
10mg
询价
3-5 天
25mg
询价
3-5 天
50mg
询价
3-5 天
100mg
询价
3-5 天
200mg
询价
询价
500mg
询价
询价

产品描述

Necrosulfonamide 是一种 MLKL 和 Gasdermin D (GSDMD) 抑制剂,可分别抑制细胞坏死性凋亡 (necroptosis) 和焦亡 (pyroptosis),其不影响上游信号激活,而是特异性抑制下游执行器的寡聚化步骤,同时可降低参与坏死性凋亡和焦亡的关键激酶 NLRP3 和 caspase-1 的表达,激活 Nrf2 通路及下游抗氧化酶,并下调多种炎症因子,从而通过调节这两条重要的程序性坏死通路,在神经退行性疾病 (如帕金森病)、组织损伤和缺血-再灌注损伤、炎症性肠病、骨关节炎和骨折修复以及脱发等多种疾病中发挥重要作用。

生物实验数据

生物活性 Necrosulfonamide is an inhibitor of MLKL and Gasdermin D (GSDMD) that inhibits necroptosis and pyroptosis, respectively; it does not affect upstream signal activation but specifically inhibits the oligomerization step of downstream executors, and it reduces the expression of the key kinases NLRP3 and caspase-1 involved in necroptosis and pyroptosis, activates the Nrf2 pathway and downstream antioxidant enzymes, and downregulates multiple inflammatory factors, thereby exerting important effects in various diseases such as neurodegenerative diseases (e.g., Parkinson's disease), tissue injury and ischemia-reperfusion injury, inflammatory bowel disease, osteoarthritis and fracture repair, and hair loss by regulating these two important programmed necrosis pathways.
IC50 & Target PI3Kγ:5.9 (pIC50), PI3Kδ:6.4 (pIC50), PI4KB:5.9 (pIC50), PI3Kβ:5.9 (pIC50), PI4Kα:8.0 (pIC50), PI4Kβ:5.9 (pIC50), PI4KA:8.0 (pIC50), PI3Kα:5.8 (pIC50)
体外研究
(In Vitro)

Necrosulfonamide (0-10 μM) 可阻断人结肠癌 HT-29 细胞和 FADD 基因敲除的人 T 细胞白血病 Jurkat 细胞的坏死,IC50 均小于 1 μM,但对小鼠细胞无此作用,原因在于,人源 MLKL 蛋白的第 86 位半胱氨酸可与其共价结合来发挥作用,但鼠源 MLKL 的第 86 位是色氨酸,而不是半胱氨酸。
Necrosulfonamide (6 小时) 作用于 RIP3 激活的下游,它不抑制 RIP1 和 RIP3 之间的相互作用或磷酸化;但在 RIP3-HT-29 细胞中会增强这些过程。
Necrosulfonamide (10 μM,45 分钟 - 25 小时) 可抑制 BMDMs 和 NCM460 细胞坏死性凋亡中炎症因子的释放和细胞焦亡,且对两种细胞的活力无影响。
Necrosulfonamide (0.1-100 μM) 可保护原代培养的星形胶质细胞和人星形胶质细胞免受氧-糖剥夺和复氧 (OGD/Re) 诱导的细胞损伤,减少 PI 阳性细胞的数量,并抑制坏死性凋亡相关蛋白的水平。
Necrosulfonamide (0.1-1 μM,6 小时) 可在 hFOB 1.19 细胞中能够通过 NLRP3/ caspase-1/GSDMD 通路逆转由细胞焦亡引起的成骨细胞增殖和分化抑制作用。

ELISA Assay

Cell Line: BMDMs
Concentration: 10 μM
Incubation Time: 1 h, followed by LPS for 6 h
Result: Inhibited the massive release of IL-1β and TNF-α.

Apoptosis Analysis

Cell Line: hFOB 1.19 cells
Concentration: 0.1, 0.5, 1 μM
Incubation Time: 6 h
Result: Significantly decreased the pyroptosis rate at 0.5 μM and 1.0 μM.
Did not significantly change the viability or pyroptosis rate of osteoblasts alone.

RT-PCR

Cell Line: hFOB 1.19 cells
Concentration: 0.1, 0.5, 1 μM
Incubation Time: 6 h
Result: Significantly decreased the pyroptosis rate at 0.5 μM and 1.0 μM.
Did not significantly change the viability or pyroptosis rate of osteoblasts alone.

Western Blot Analysis

Cell Line: hFOB 1.19 cells
Concentration: 0.1, 0.5, 1 μM
Incubation Time: 6 h
Result: Inhibited the activation of the pyroptosis execution proteins (caspase-1, GSDMD).
Increased the protein expressions of key osteogenic markers (ALP, Runx2, COL-1, OPN, BMP-2)

ELISA Assay

Cell Line: hFOB 1.19 cells
Concentration: 0.1, 0.5, 1 μM
Incubation Time: 6 h
Result: Reduced the levels of IL-6, TNF-α and IL-1β in the cell supernatant
体内研究
(In Vivo)

Necrosulfonamide (20 mg/kg,腹腔注射,单剂量) 可缓解 Lipopolysaccharide (MS-S99407)/ D-galactosamine (MS-P11696) 诱导的小鼠急性肝衰竭。
Necrosulfonamide (1-5 mg/kg,腹腔注射,每日一次,连续 3 天) 可减少MPTP (MS-P76578) 诱导的帕金森病小鼠模型中的氧化应激、炎症和多巴胺能神经元细胞死亡。
Necrosulfonamide (20-40 mg/kg,腹腔注射,每日一次,连续 5-7 天) 能够改善小鼠的炎症性肠病 (IBD),其机制在于抑制由 GSDMD 介导的细胞焦亡以及由 MLKL 介导的坏死性凋亡。
Necrosulfonamide (40-80 nmol,脑室内给药,单剂量) 对大鼠缺血/再灌注 (I/R) 诱发的急性脑损伤具有神经保护作用。
Necrosulfonamide 通过 Wnt 信号传导促进雄激素性脱发 (AGA) 小鼠的毛发生长并防止毛囊退化。

Animal Model: LPS/D-galactosamine-induced acute liver failure established in male 8-week-old specific pathogen-free (SPF) grade C57BL/6J mice
Dosage: 20 mg/kg
Administration: Intraperitoneal injection (i.p.), single dose before the model creation process
Result: Increased the survival rate of mice, reduced the serum ALT level, and alleviated liver tissue damage.
Reduced the levels of serum IL-1β and IL-18.
Downregulated the protein levels of NLRP3, cleaved caspase-1, cleaved caspase-11, and mature IL-1β.
Animal Model: MPTP-induced Parkinson’s disease mouse model established in male C57BL/6 mice (24-25 g, 9-10 weeks old)
Dosage: 1 and 5 mg/kg
Administration: Intraperitoneal injection (i.p.), single dose before the model creation process
Result: Reduced the death of dopaminergic neurons and restores neurotrophic factors.
Reduced the levels of pro-inflammatory mediators such as iNOS, TNF-α, IL-1β, and IL-6.
Reduced the activation of microglial cells and astrocytes in the substantia nigra and striatum.
Restored the expression of the core antioxidant transcription factor Nrf2 and a series of downstream antioxidant enzymes (HO-1, catalase, MnSOD, GCLC, GCLM).
Effectively inhibited the expression of p-MLKL and MLKL, and reduced the number of p-MLKL+/TH+ and p-MLKL+/OX-42+ cells.
Animal Model: DSS (MS-A45736) induced IBD model established in male 6- to 9-week-old C57BL/6 mice weighting 22-26 g
Dosage: 20 and 40 mg/kg (prevent) and 20 mg/kg (treatment)
Administration: Intraperitoneal injection (i.p.), once every other day for 7 days (prevent) and for 5 days (treatment)
Result: Significantly reduced the DAI score and increased the colon length in a dose-dependent manner.
Reduced the levels of serum TNF-α and MPO.
Reduced the inflammatory score, retained more goblet cells and mucus layers, and decreased the infiltration of CD4+ T cells, CD8+ T cells and macrophages (F4/80+) in the colon tissue.
Reduced the levels of 16sRNA, IL-1β, TNF-α, and IL-6 mRNA, inhibited p-p65, and promoted Nrf2 expression.
Reduced the death of colonic epithelial cells and p-MLKL-positive cells, and inhibited the expression of necroptosis markers (p-MLKL, p-RIPK1, p-RIPK3) and pyroptosis markers (N-GSDMD).
Animal Model: Transient middle cerebral artery occlusion model established in adult male SD rats (290-310 g)
Dosage: 40 and 80 nmol
Administration: Intracerebroventricular administration, single dose
Result: Significantly reduced the volume of cerebral infarction.
Significantly improved the neurological function score and the asymmetry of forelimb usage.
Significantly reduced the number of PI-positive cells.
Inhibited the total expression levels of MLKL/p-MLKL, RIP3K/p-RIP3K, and RIP1K/p-RIP1K in the ischemic penumbra tissue, and translocation of MLKL/p-MLKL and RIP3K/p-RIP3K to the nucleus and nuclear membrane.
性状 固体
颜色 Light yellow to yellow

化学信息

分子量 461.47
分子式 C18H15N5O6S2
CAS No. 1360614-48-7

储存&溶解度

储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 2 years
-20°C 1 year
运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : ≥ 28 mg/mL (60.68 mM; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

* "≥" means soluble, but saturation unknown.

可选溶剂浓度1 mg5 mg10 mg25 mg
DMSO1 mM2.1670 mL10.8349 mL21.6699 mL54.1747 mL
5 mM0.4334 mL2.1670 mL4.3340 mL10.8349 mL
10 mM0.2167 mL1.0835 mL2.1670 mL5.4175 mL
15 mM0.1445 mL0.7223 mL1.4447 mL3.6116 mL
20 mM0.1083 mL0.5417 mL1.0835 mL2.7087 mL
25 mM0.0867 mL0.4334 mL0.8668 mL2.1670 mL
30 mM0.0722 mL0.3612 mL0.7223 mL1.8058 mL
40 mM0.0542 mL0.2709 mL0.5417 mL1.3544 mL
50 mM0.0433 mL0.2167 mL0.4334 mL1.0835 mL
60 mM0.0361 mL0.1806 mL0.3612 mL0.9029 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 2 years; -20°C, 1 year。-80°C储存时,请在2年内使用, -20°C储存时,请在1年内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

Necrosulfonamide 相关分类

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础